The final, formatted version of the article will be published soon.
REVIEW article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1423143
This article is part of the Research Topic Exploring Oncolytic Virotherapy in Solid Tumor Treatment View all 3 articles
The investigation of oncolytic viruses in the field of cancer therapy
Provisionally accepted
Zijun Yuan
1,2*
Yinping Zhang
2
Xiang Wang
2*
Xingyue Wang
2*
Siqi Ren
2*
Xinyu He
2*
Jiahong Su
2*
Anfu Zheng
2*
Sipeng Guo
3*
Yu Chen
2
Shuai Deng
2*
XU WU
2
Mingxing Li
2
Fukuan Du
2*
YUESHUI ZHAO
2
Jing Shen
2
Zechen Wang
1*
Zhangang Xiao
1,2,4,5*- 1 Gulin People’s Hospital Sichuan, Luzhou, China
- 2 Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Lu Zhou, China
- 3 Research And Experiment Center, Sichuan College of Traditional Chinese Medicine, Mianyang, China
- 4 Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan Province, China
- 5 South Sichuan Institute of Translational Medicine, Southwest Medical University, Luzhou, Sichuan Province, China
Oncolytic viruses (OVs) have emerged as a potential strategy for tumor treatment due to their ability to selectively replicate in tumor cells, induce apoptosis, and stimulate immune responses. However, the therapeutic efficacy of single OVs is limited by the complexity and immunosuppressive nature of the tumor microenvironment (TME). To overcome these challenges, engineering OVs has become an important research direction. This review focuses on engineering methods and multi-modal combination therapies for OVs aimed at addressing delivery barriers, viral phagocytosis, and antiviral immunity in tumor therapy. The engineering approaches discussed include enhancing in vivo immune response, improving replication efficiency within the tumor cells, enhancing safety profiles, and improving targeting capabilities. In addition, this review describes the potential mechanisms of OVs combined with radiotherapy, chemotherapy, cell therapy and immune checkpoint inhibitors (ICIs), and summarizes the data of ongoing clinical trials. By continuously optimizing engineering strategies
Keywords: Oncolytic Viruses, cancer therapy, Genetic Engineering, combination therapy, clinical trials
Received: 25 Apr 2024; Accepted: 26 Jun 2024.
Copyright: © 2024 Yuan, Zhang, Wang, Wang, Ren, He, Su, Zheng, Guo, Chen, Deng, WU, Li, Du, ZHAO, Shen, Wang and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zijun Yuan, Gulin People’s Hospital Sichuan, Luzhou, China
Xiang Wang, Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Lu Zhou, China
Xingyue Wang, Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Lu Zhou, China
Siqi Ren, Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Lu Zhou, China
Xinyu He, Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Lu Zhou, China
Jiahong Su, Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Lu Zhou, China
Anfu Zheng, Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Lu Zhou, China
Sipeng Guo, Research And Experiment Center, Sichuan College of Traditional Chinese Medicine, Mianyang, China
Shuai Deng, Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Lu Zhou, China
Fukuan Du, Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Lu Zhou, China
Zechen Wang, Gulin People’s Hospital Sichuan, Luzhou, China
Zhangang Xiao, Gulin People’s Hospital Sichuan, Luzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.